
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees is looking to expand in the infectious disease market with its unique pipeline of therapies aimed at vector-borne, fungal, and viral diseases, which have limited treatment options currently available. Its successful commercial efforts have led to steady growth in its product revenues, which is expected to increase further with initiatives to increase awareness and market access for its lead asset, Arakoda, used in preventing certain types of malaria. Despite recent financing activities and a reverse stock split, analysts remain bullish on the company's prospects, citing its potential for further partnerships and approvals in additional indications. Risks include clinical trial outcomes and potential dilution from future financings.
Bears say
60 Degrees is facing a setback to revenue growth with its market access partnership with Runway Health - a new pillar to the company's ARKODA marketing strategy - being delayed until April 2026. While the company has broadened its pipeline with the submission of a notification to the FDA for Australian Chestnut Extract, there is a risk of gross margins being negatively impacted in the short-term due to a one-time inventory write-off. However, the company is confident in the potential of its product for babesiosis, reaffirming its blockbuster potential and securing a strong position in the TAM market.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares